Genomic Health Reports Favorable Commentary On Value Of Multigene Assays From The St. Gallen Expert Consensus Meeting On The Primary Treatment Of Early Breast Cancer

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

Genomic Health, Inc. today reported that the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer recommended for the first time that validated multigene assays, such as Oncotype DX(R), should be considered as an adjunct to standard measures in helping determine chemotherapy benefit for early-stage breast cancer patients.

 

0 Comments

You must be logged in to post comments.

We care about your feedback. Let us know how we can improve your CancerCompass experience.